Advances and challenges in drug design of PPARδ ligands (2018)
Fonte: Current Drug Targets. Unidades: ICB, FCF, EACH
Assuntos: DIABETES MELLITUS NÃO INSULINO-DEPENDENTE, SÍNDROME X METABÓLICA, ÁCIDOS GRAXOS, DOENÇAS METABÓLICAS, PARASITOLOGIA
ABNT
MALTAROLLO, Vinícius Gonçalves et al. Advances and challenges in drug design of PPARδ ligands. Current Drug Targets, v. 19, n. 2, p. 144-154, 2018Tradução . . Disponível em: https://doi.org/10.2174/1389450118666170414113159. Acesso em: 18 nov. 2024.APA
Maltarollo, V. G., Kronenberger, T., Windshuegel, B., Wrenger, C., Trossini, G. H. G., & Honório, K. M. (2018). Advances and challenges in drug design of PPARδ ligands. Current Drug Targets, 19( 2), 144-154. doi:10.2174/1389450118666170414113159NLM
Maltarollo VG, Kronenberger T, Windshuegel B, Wrenger C, Trossini GHG, Honório KM. Advances and challenges in drug design of PPARδ ligands [Internet]. Current Drug Targets. 2018 ; 19( 2): 144-154.[citado 2024 nov. 18 ] Available from: https://doi.org/10.2174/1389450118666170414113159Vancouver
Maltarollo VG, Kronenberger T, Windshuegel B, Wrenger C, Trossini GHG, Honório KM. Advances and challenges in drug design of PPARδ ligands [Internet]. Current Drug Targets. 2018 ; 19( 2): 144-154.[citado 2024 nov. 18 ] Available from: https://doi.org/10.2174/1389450118666170414113159